Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed the day trading at $5.8 down -15.70% from the previous closing price of $6.88. In other words, the price has decreased by -$15.70 from its previous closing price. On the day, 9.26 million shares were traded. DAWN stock price reached its highest trading level at $6.09 during the session, while it also had its lowest trading level at $5.635.
Ratios:
For a better understanding of DAWN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.53 and its Current Ratio is at 9.65. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 16 ’25 when Merendino Lauren sold 3,927 shares for $6.26 per share. The transaction valued at 24,575 led to the insider holds 35,161 shares of the business.
Dubow Adam sold 4,552 shares of DAWN for $28,486 on May 16 ’25. The GENERAL COUNSEL now owns 47,136 shares after completing the transaction at $6.26 per share. On May 16 ’25, another insider, York Charles N II, who serves as the COO, CFO AND SECRETARY of the company, sold 4,282 shares for $6.26 each. As a result, the insider received 26,796 and left with 265,231 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 594105600 and an Enterprise Value of 144005216. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.13 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at 0.767 whereas that against EBITDA is -1.387.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.27, which has changed by -0.55826354 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $16.76, while it has fallen to a 52-week low of $6.08. The 50-Day Moving Average of the stock is -13.40%, while the 200-Day Moving Average is calculated to be -41.13%.
Shares Statistics:
Over the past 3-months, DAWN traded about 1.48M shares per day on average, while over the past 10 days, DAWN traded about 2560340 shares per day. A total of 102.43M shares are outstanding, with a floating share count of 74.67M. Insiders hold about 26.33% of the company’s shares, while institutions hold 84.48% stake in the company. Shares short for DAWN as of 1752537600 were 10280741 with a Short Ratio of 6.96, compared to 1749772800 on 12608785. Therefore, it implies a Short% of Shares Outstanding of 10280741 and a Short% of Float of 15.09.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of Day One Biopharmaceuticals Inc (DAWN) is currently shaped by the ongoing analysis conducted by 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.31 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$1.12 and -$1.35 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$0.92, with 5.0 analysts recommending between -$0.4 and -$1.42.
Revenue Estimates
7 analysts predict $38.58M in revenue for the current quarter. It ranges from a high estimate of $41M to a low estimate of $36.75M. As of the current estimate, Day One Biopharmaceuticals Inc’s year-ago sales were $93.76MFor the next quarter, 7 analysts are estimating revenue of $41.99M. There is a high estimate of $47M for the next quarter, whereas the lowest estimate is $37.9M.
A total of 8 analysts have provided revenue estimates for DAWN’s current fiscal year. The highest revenue estimate was $151M, while the lowest revenue estimate was $139.32M, resulting in an average revenue estimate of $145.3M. In the same quarter a year ago, actual revenue was $131.16MBased on 9 analysts’ estimates, the company’s revenue will be $217.14M in the next fiscal year. The high estimate is $295M and the low estimate is $171.12M.
